Research publications

Alfred Health research outcomes are published in a wide range of peer reviewed journals. 

Search or browse research publications by year, research area, publication type or keyword.

Clear filter
Publication Details
Personalized cancer immunotherapy: Today's challenge and tomorrow's promise

Ameratunga M, Xu W, Lopez J

(2018), J Immunother Precis Oncol, 1, 56-67

DOI: 10.4103/JIPO.JIPO_13_18

CNS cancer immunity cycle and strategies to target this for glioblastoma

Ameratunga M, Coleman N, Welsh L, Saran F, Lopez J

(2018), Oncotarget, 9(32), 22802-22816

DOI: 10.18632/oncotarget.24896

Clinical outcomes of adolescents and young adults with advanced solid tumours participating in phase I trials

Sundar R, McVeigh T, Dolling D, Petruckevitch A, Diamantis N, Ang JE, Chenard-Poiri»r M, Collins D, Lim J, Ameratunga M, Khan K, Kaye SB, Banerji U, Lopez J, George AJ, de Bono JS, van der Graaf WT

(2018), Eur J Cancer, 101, 55-61

DOI: 10.1016/j.ejca.2018.06.003

A single-institution prospective evaluation of a neuro-oncology multidisciplinary team meeting

Ameratunga M, Miller D, Ng W, Wada M, Gonzalvo A, Cher L, Gan HK

(2018), J Clin Neurosci, 56, 127-130

DOI: 10.1016/j.jocn.2018.06.032

A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trials

Ingles Garces AH, Ang JE, Ameratunga M, Ch»nard-Poirier M, Dolling D, Diamantis N, Seeramreddi S, Sundar R, de Bono J, Lopez J, Banerji U

(2018), Eur J Cancer, 104, 32-38

DOI: 10.1016/j.ejca.2018.08.019

The value of participating in clinical trials: the whole is greater than the sum of its parts

Zalcberg JR, Friedlander M

(2018), Med J Aust, 209(10), 424-425

DOI: 10.5694/mja17.01266

Feasibility of 5-fluorouracil pharmacokinetic monitoring using the My-5FU PCM™ system in a quaternary oncology centre

Moloney M, Faulkner D, Link E, Rischin D, Solomon B, Lim AM, Zalcberg JR, Jefford M, Michael M

(2018), Cancer Chemother Pharmacol, 82(5), 865-876

DOI: 10.1007/s00280-018-3679-4

Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW

Muro K, Cho JY, Bodoky G, Goswami C, Chao Y, Dos Santos LV, Shimada Y, Topuzov E, Van Cutsem E, Tabernero J, Zalcberg J, Chau I, Cascinu S, Cheng R, Hsu Y, Emig M, Orlando M, Fuchs C

(2018), J Gastroenterol Hepatol, 33(4), 814-824

DOI: 10.1111/jgh.14007

Biosimilars are coming: ready or not

Zalcberg J

(2018), Intern Med J, 48(9), 1027-1034

DOI: 10.1111/imj.14033

Rationale, Opportunities, and Reality of Biosimilar Medications

Zalcberg JR

(2018), N Engl J Med, 379(7), 694

DOI: 10.1056/NEJMc1808348

Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group

Goey KKH, Sørbye H, Glimelius B, Adams RA, Andr» T, Arnold D, Berlin JD, Bodoky G, de Gramont A, DÃaz-Rubio E, Eng C, Falcone A, Grothey A, Heinemann V, Hochster HS, Kaplan RS, Kopetz S, Labianca R, Lieu CH, Meropol NJ, Price TJ, Schilsky RL, Schmoll HJ, Shacham-Shmueli E, Shi Q, Sobrero AF, Souglakos J, Van Cutsem E, Zalcberg J, van Oijen MGH, Punt CJA, Koopman M

(2018), Eur J Cancer, 100, 35-45

DOI: 10.1016/j.ejca.2018.05.010

Telehealth

Sabesan S, Zalcberg J

(2018), N Engl J Med, 378(4), 402

DOI: 10.1056/NEJMc1715239

Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project

Sjoquist KM, Renfro LA, Simes RJ, Tebbutt NC, Clarke S, Seymour MT, Adams R, Maughan TS, Saltz L, Goldberg RM, Schmoll HJ, Van Cutsem E, Douillard JY, Hoff PM, Hecht JR, Tournigand C, Punt CJA, Koopman M, Hurwitz H, Heinemann V, Falcone A, Porschen R, Fuchs C, Diaz-Rubio E, Aranda E, Bokemeyer C, Souglakos I, Kabbinavar FF, Chibaudel B, Meyers JP, Sargent DJ, de Gramont A, Zalcberg JR; Fondation Aide et Recherche en Cancerologie Digestive Group (ARCAD)

(2018), J Natl Cancer Inst, 110(6), 638-648

DOI: 10.1093/jnci/djx253

Effect of 6 months hybrid closed-loop insulin delivery in young people with type 1 diabetes: a randomised controlled trial protocol

de Bock M, McAuley SA, Abraham MB, Smith G, Nicholas J, Ambler GR, Cameron FJ, Fairchild JM, King BR, Geelhoed EA, Davis EA, O'Neal DN, Jones TW; Australian JDRF Closed-Loop Research Group

(2018), BMJ Open, 8(8), e020275

DOI: 10.1136/bmjopen-2017-020275

Making sense of newer treatment options for type 2 diabetes

Lee PC, Hare MJL, Bach LA

(2018), Intern Med J, 48(7), 762-769

DOI: 10.1111/imj.13947

IGF-binding proteins

Bach LA

(2018), J Mol Endocrinol, 61(1), T11-28

DOI: 10.1530/JME-17-0254

Differential expression of IGFBPs in Laron syndrome-derived lymphoblastoid cell lines: Potential correlation with reduced cancer incidence

Somri L, Sarfstein R, Lapkina-Gendler L, Nagaraj K, Laron Z, Bach LA, Werner H

(2018), Growth Horm IGF Res, 39, 43628

DOI: 10.1016/j.ghir.2017.11.004

What Happened to the IGF Binding Proteins?

Bach LA

(2018), Endocrinology, 159(2), 570-578

DOI: 10.1210/en.2017-00908

Awareness and use of iodine supplementation among Australian women attending a low-risk pregnancy clinic

Cooray SD, Langston-Cox AG, Robinson PJ, Bahemia N, Davis SR, Bell RJ, Topliss DJ, Schneider HG, Sztal-Mazer S

(2018), Aust N Z J Obstet Gynaecol, 58(5), e16-17

DOI: 10.1111/ajo.12829

Clinical guidance for radioiodine refractory differentiated thyroid cancer

Gild ML, Topliss DJ, Learoyd D, Parnis F, Tie J, Hughes B, Walsh JP, McLeod DSA, Clifton-Bligh RJ, Robinson BG

(2018), Clin Endocrinol, 88(4), 529-537

DOI: 10.1111/cen.13508

336 337 338 339 340